Using millers anaesthesiology book discuss in details Novel anticoagulants NOAC
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from Miller's Anesthesia. Let me compile the full detailed response.
Novel Anticoagulants (NOACs / DOACs)
From Miller's Anesthesia, 10th Edition
1. Introduction and Classification
Several new oral anticoagulants have been introduced since 2010, now more formally called Direct Oral Anticoagulants (DOACs) — though still referred to as NOACs (Novel Oral Anticoagulants) in the literature. These drugs offer more predictable pharmacokinetics and pharmacodynamics and fewer drug-drug interactions than older agents, allowing dosing without the need for daily laboratory monitoring.
DOACs are divided into two categories:
| Category | Drug(s) | Target |
|---|---|---|
| Direct Thrombin Inhibitors (DTIs) | Dabigatran (Pradaxa) | Factor IIa (thrombin) |
| Direct Factor Xa Inhibitors | Rivaroxaban (Xarelto), Apixaban (Eliquis), Edoxaban (Savaysa) | Factor Xa |
— Miller's Anesthesia, 10e, Chapter 46 (Hemostasis & Anticoagulation)
2. Approved Indications
Most DOACs are approved for:
- Prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Reduction of stroke risk in nonvalvular atrial fibrillation (AF)
- In patients with AF undergoing percutaneous coronary intervention (PCI), dual therapy (a Factor Xa inhibitor + a P2Y12 inhibitor) reduces bleeding risk compared with triple therapy (VKA + ASA + P2Y12 inhibitor), though end points of death and ischemia remain unclear.
3. Efficacy vs. Warfarin
DOACs have a shorter half-life than warfarin and have demonstrated non-inferior efficacy to warfarin.
A meta-analysis of phase 2 and phase 3 randomized clinical trials comparing DOACs with VKAs in patients with nonvalvular AF showed:
- Significant reduction in major bleeding (RR 0.86, 95% CI 0.72–1.02)
- Significantly decreased risk of intracranial hemorrhage (RR 0.46, 95% CI 0.39–0.56)
Important contraindication: DOACs are contraindicated in patients with mechanical heart valves — VKA (warfarin) remains the preferred agent due to excess thromboembolic and bleeding events seen in a phase 2 dose-validation study that had to be terminated prematurely.
4. Individual Drugs
A. Dabigatran (Pradaxa) — Direct Thrombin Inhibitor
- First DOAC approved for stroke prevention in nonvalvular AF since warfarin
- At 150 mg twice daily: reduces stroke risk with a similar overall bleeding risk to warfarin (INR 2.0–3.0)
- Bleeding profile differs: higher risk of major gastrointestinal bleeding, but lower risk of intracranial bleeding vs. warfarin
- Monitoring challenge: aPTT is non-linear at clinically relevant concentrations (only correlates at >200 ng/mL). The thrombin time (TT) is very sensitive but cannot quantify drug levels. If monitoring is necessary, dilute TT or ecarin clotting time are the tests of choice.
B. Rivaroxaban (Xarelto) — Factor Xa Inhibitor
- Activity directed against the active site of factor Xa
- Associated with fewer strokes/embolic events, fewer intracranial hemorrhages, and lower all-cause mortality vs. warfarin
- Monitoring: anti-factor Xa assay (must be calibrated individually for each drug; therapeutic ranges not yet established)
C. Apixaban (Eliquis) — Factor Xa Inhibitor
- Compared with warfarin in patients with AF: reduction in stroke risk plus a significant reduction in major bleeding
- Monitoring: anti-factor Xa assay (same caveats as rivaroxaban)
D. Edoxaban (Savaysa) — Factor Xa Inhibitor
- Similar mechanism to rivaroxaban and apixaban
- Used for DVT/PE treatment and AF stroke prevention
- Note: the reversal agent andexanet alfa is not currently indicated for edoxaban
5. Special Populations and Dose Adjustments
Comorbidities requiring dose adjustment or alternative anticoagulants:
- Renal or hepatic impairment — dose adjustments are drug-specific
- Extreme body weights — <60 kg or BMI >40 kg/m² may alter pharmacokinetics
- Pregnancy — LMWH is preferred over DOACs in most pregnant women requiring anticoagulation
- Mechanical heart valves — DOACs are contraindicated; use warfarin
6. Perioperative Management
6a. Preoperative Discontinuation
Patients increasingly receive DOACs for nonvalvular AF or low-dose for IHD. Timing of preoperative discontinuation is guided by:
- The specific DOAC prescribed
- Expected procedural bleeding risk
- Renal function (eGFR)
- Whether neuraxial anesthesia is planned
DOAC discontinuation timing (from ASRA 2018 guidelines and Miller's Table 28.11):
| Drug | Low-bleeding risk procedure | High-bleeding risk procedure / Neuraxial |
|---|---|---|
| Dabigatran | 24 h before | 48–96 h (renal function dependent) |
| Rivaroxaban | 24 h | 48 h |
| Apixaban | 24 h | 48 h |
| Edoxaban | 24 h | 48 h |
6b. Bridging Therapy
Unlike VKAs (which often need bridging therapy due to their long half-life), bridging therapy is generally NOT needed after interruption of DOACs because of their relatively short half-lives. Most patients with nonvalvular AF do not require bridging if anticoagulant therapy is temporarily discontinued before surgery.
Bridging may still be considered for:
- Some patients with mechanical heart valves (decision based on valve location and surgery type)
- Patients at high risk for recurrent thromboembolism
6c. Neuraxial Anesthesia
Management of perioperative anticoagulation is increasingly complex with DOACs, and most guidelines are based on pharmacokinetic/pharmacodynamic principles rather than RCT data. Key points:
- Wait the recommended interval (above) after last DOAC dose before neuraxial block
- Multidisciplinary team approach (patient, primary physician, surgeon, anesthesiologist, hematologist) is essential
- Local hospital guidelines are being set in the absence of definitive RCT data
6d. Cardiac Surgery Patients on DOACs
Patients with AF may present on DOACs (dabigatran, rivaroxaban, apixaban, edoxaban). These drugs add complexity to cardiac surgical management given the additional bleeding risk from CPB itself. Decision-making involves drug-specific pharmacology and bleeding risk assessment.
6e. Ophthalmic Surgery
There are limited data on NOAC management in ophthalmic surgery. Some authors recommend cessation of NOACs one day before surgeries with higher hemorrhagic risk (e.g., oculoplastic, vitreoretinal). Cataract surgery generally carries the lowest hemorrhagic risk.
7. Reversal Agents
7a. Dabigatran Reversal — Idarucizumab (Praxbind)
- A humanized antibody fragment that binds dabigatran with an affinity 350 times greater than thrombin
- Median time to hemostasis: 2.5 hours in patients with GI, intracerebral, or traumatic bleeding
- Specific antidote for dabigatran
7b. Factor Xa Inhibitor Reversal — Andexanet Alfa (Andexxa)
- A recombinant derivative of factor Xa that acts as a decoy receptor for factor Xa inhibitors
- Has higher affinity for factor Xa inhibitors than intrinsic factor Xa
- FDA-approved for acute hemorrhage in patients on apixaban or rivaroxaban
- Current indication does not cover edoxaban or enoxaparin
- Outcomes: 92% reduction in anti-Xa activity; hemostasis judged good or excellent in most
- Important caveat: 10% of 352 patients had a thrombotic event within 30 days — FDA issued a black box warning for risk of venous and arterial thromboembolic events
7c. Emerging Reversal Agent — Ciraparantag (PER977)
- A small, synthetic, water-soluble, cationic molecule
- Binds and neutralizes: UFH, LMWH, fondaparinux, dabigatran, and factor Xa inhibitors through hydrogen bonding and charge–charge interactions
- Phase 2 trials completed in healthy volunteers — represents a universal reversal agent in development
7d. General Supportive Measures for DOAC Bleeding
Before reaching for reversal agents (which should be reserved for life-threatening hemorrhage):
- Discontinue medications interfering with hemostasis
- Compression of the bleeding site
- Volume resuscitation and transfusion support
- Antifibrinolytic therapy (e.g., tranexamic acid) for mucosal bleeding
- Activated charcoal — may remove unabsorbed dabigatran from the GI tract
- Desmopressin — for impaired platelet function in uremia or with antiplatelet agents
- PCCs or aPCCs have been used off-label but very little conclusive data exist vs. specific reversal agents
8. Laboratory Monitoring Summary
| Drug | Routine monitoring needed? | Best available test if needed |
|---|---|---|
| Dabigatran | No | Dilute TT or Ecarin Clotting Time |
| Rivaroxaban | No | Anti-Xa assay (calibrated for rivaroxaban) |
| Apixaban | No | Anti-Xa assay (calibrated for apixaban) |
| Edoxaban | No | Anti-Xa assay (calibrated for edoxaban) |
Note: therapeutic ranges for anti-Xa assays have not been established or correlated with clinical outcomes for DOACs.
9. Key Advantages of DOACs over VKAs
| Feature | DOACs | Warfarin (VKA) |
|---|---|---|
| Pharmacokinetics | Predictable | Variable |
| Drug-drug interactions | Fewer | Many |
| Routine monitoring | Not required | Required (INR) |
| Onset | Rapid | Slow (days) |
| Half-life | Short (hours) | Long (days–weeks) |
| Intracranial hemorrhage risk | Lower | Higher |
| GI bleeding (dabigatran) | Higher | Lower |
| Reversal | Specific antidotes available | Vitamin K + PCC/FFP |
| Mechanical valve use | Contraindicated | Preferred |
Key Clinical Takeaways from Miller's Anesthesia
- DOACs do not require routine monitoring but specific tests can detect drug presence when needed
- Bridging therapy is generally not required when DOACs are held perioperatively
- ASRA 2018 guidelines guide timing of neuraxial anesthesia in patients on DOACs
- Reversal agents exist (idarucizumab for dabigatran; andexanet alfa for apixaban/rivaroxaban) but should be reserved for life-threatening hemorrhage
- Andexanet alfa carries a black box warning for thromboembolic events
- Multidisciplinary perioperative planning is essential for patients on chronic DOAC therapy
- DOACs are absolutely contraindicated in mechanical heart valve patients
Sources: Miller's Anesthesia, 2-Volume Set, 10e — Chapters 28 (Preoperative Evaluation), 46 (Hemostasis and Transfusion Medicine), 48 (Cardiac Surgery), and 65 (Ophthalmic Anesthesia)
Now shorten it to most exam answer appropriate notes including almost every important thing
Checking Date & Time
NOACs / DOACs — High-Yield Exam Notes
(Miller's Anesthesia, 10e)
Classification
| Class | Drug | Brand |
|---|---|---|
| Direct Thrombin Inhibitor (DTI) | Dabigatran | Pradaxa |
| Factor Xa Inhibitor | Rivaroxaban | Xarelto |
| Factor Xa Inhibitor | Apixaban | Eliquis |
| Factor Xa Inhibitor | Edoxaban | Savaysa |
Key Advantages Over Warfarin
- Predictable PK/PD → no routine monitoring needed
- Fewer drug-drug interactions
- Rapid onset, short half-life
- Lower intracranial hemorrhage risk
- Contraindicated in mechanical heart valves (use warfarin)
- LMWH preferred over DOACs in pregnancy
Indications
- Nonvalvular AF → stroke prevention
- DVT / PE → prevention & treatment
- AF + PCI → dual therapy (Xa inhibitor + P2Y12) preferred over triple therapy
Individual Drug Facts
Dabigatran (DTI)
- 150 mg BD: non-inferior to warfarin for stroke; similar overall bleeding risk
- ↑ GI bleeding, ↓ intracranial bleeding vs. warfarin
- Monitoring: aPTT unreliable; dilute TT or ecarin clotting time = tests of choice; TT very sensitive (detects presence but not quantity)
Rivaroxaban / Apixaban / Edoxaban (Xa inhibitors)
- ↓ strokes, ↓ intracranial hemorrhage, ↓ all-cause mortality vs. warfarin
- Apixaban vs. warfarin: ↓ stroke + significant ↓ major bleeding
- Monitoring: anti-Xa assay (must be individually calibrated per drug; no established therapeutic range)
Perioperative Management
Preoperative hold (ASRA 2018 guidelines):
| Drug | Low-risk surgery | High-risk / Neuraxial |
|---|---|---|
| Dabigatran | 24 h | 48–96 h (↑ if renal impairment) |
| Rivaroxaban | 24 h | 48 h |
| Apixaban | 24 h | 48 h |
| Edoxaban | 24 h | 48 h |
Bridging therapy: Generally NOT needed for DOACs (short half-life). May be needed for mechanical valves or high thrombotic risk.
Neuraxial anesthesia: Follow above intervals. Guidelines largely based on PK/PD (not RCT data). Multidisciplinary approach essential.
Reversal Agents
| Agent | Reverses | Mechanism | Key Points |
|---|---|---|---|
| Idarucizumab (Praxbind) | Dabigatran | Antibody fragment; binds dabigatran 350× > thrombin | Median hemostasis: 2.5 h |
| Andexanet alfa (Andexxa) | Apixaban, Rivaroxaban | Recombinant factor Xa decoy | FDA-approved; ⚠️ Black box warning: 10% thrombotic events within 30 days; NOT indicated for edoxaban or enoxaparin |
| Ciraparantag (PER977) | UFH, LMWH, fondaparinux, dabigatran, Xa inhibitors | Cationic molecule; hydrogen bonding | Phase 2 trials only; universal reversal agent |
Supportive measures first (before reversal agents):
- Stop offending agents; compression; resuscitation
- Activated charcoal (for unabsorbed dabigatran)
- Antifibrinolytics (mucosal bleeding)
- Desmopressin (platelet dysfunction/uremia)
- Reversal agents: reserve for life-threatening hemorrhage
Meta-analysis Figures (High-Yield Numbers)
- Major bleeding: RR 0.86 (95% CI 0.72–1.02) vs. warfarin
- Intracranial hemorrhage: RR 0.46 (95% CI 0.39–0.56) vs. warfarin
Quick Comparison Table
| Feature | DOACs | Warfarin |
|---|---|---|
| Monitoring | Not routine | INR required |
| Bridging needed | Usually NO | Often YES |
| Mechanical valves | ❌ Contraindicated | ✅ Preferred |
| Intracranial bleed | ↓ | ↑ |
| GI bleed (dabigatran) | ↑ | ↓ |
| Reversal | Specific antidotes | Vit K + PCC |
This is a shared conversation. Sign in to Orris to start your own chat.